Gene expression data, collected from ASPS tumors of seven different patients and from one immortalized ASPS cell line (ASPS-1), was analyzed jointly with patient ASPL-TFE3 (t(X;17)(p11;q25)) fusion transcript data to identify disease-specific pathways and their component genes. Data analysis of the pooled patient and ASPS-1 gene expression data, using conventional clustering methods, revealed a relatively small set of pathways and genes characterizing the biology of ASPS. These results could be largely recapitulated using only the gene expression data collected from patient tumor samples. The concordance between expression measures derived from ASPS-1 and both pooled and individual patient tumor data provided a rationale for extending the analysis to include patient ASPL-TFE3 fusion transcript data. A novel linear model was exploited to link gene expressions to fusion transcript data and used to identify a small set of ASPS-specific pathways and their gene expression. Cellular pathways that appear aberrantly regulated in response to the t(X;17)(p11;q25) translocation include the cell cycle and cell adhesion. The identification of pathways and gene subsets characteristic of ASPS support current therapeutic strategies that target the FLT1 and MET, while also proposing additional targeting of genes found in pathways involved in the cell cycle (CHK1), cell adhesion (ARHGD1A), cell division (CDC6), control of meiosis (RAD51L3) and mitosis (BIRC5), and chemokine-related protein tyrosine kinase activity (CCL4).
References
[1]
Lamb J (2007) The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 7: 54–60.
[2]
Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929–1935.
[3]
Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, et al. (2011) Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 3: 96ra77.
[4]
Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267–273.
[5]
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545–15550.
[6]
Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44–57.
[7]
Goley EM, Anderson SJ, Menard C, Chuang E, Lu X, et al. (2004) Microarray analysis in clinical oncology: pre-clinical optimization using needle core biopsies from xenograft tumors. BMC Cancer 4: 20.
[8]
Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, et al. (2003) Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 97: 2960–2971.
[9]
Christopherson WM, Foote FW Jr, Stewart FW (1952) Alveolar soft-part sarcomas; structurally characteristic tumors of uncertain histogenesis. Cancer 5: 100–111.
[10]
Sandberg A, Bridge J (2002) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: alveolar soft part sarcoma. Cancer Genet Cytogenet 136: 1–9.
[11]
Reichardt P, Lindner T, Pink D, Thuss-Patience PC, Kretzschmar A, et al. (2003) Chemotherapy in alveolar soft part sarcomas. What do we know? Eur J Cancer 39: 1511–1516.
[12]
Portera CA Jr, Ho V, Patel SR, Hunt KK, Feig BW, et al. (2001) Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer 91: 585–591.
[13]
Heimann P, Devalck C, Debusscher C, Sariban E, Vamos E (1998) Alveolar soft-part sarcoma: further evidence by FISH for the involvement of chromosome band 17q25. Genes Chromosomes Cancer 23: 194–197.
[14]
Ladanyi M, Lui MY, Antonescu CR, Krause-Boehm A, Meindl A, et al. (2001) The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 20: 48–57.
[15]
Vistica DT, Hollingshead M, Borgel SD, Kenney S, Stockwin LH, et al. (2009) Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy. J Pediatr Hematol Oncol 31: 561–570.
[16]
Kenney S, Vistica DT, Stockwin LH, Burkett S, Hollingshead MG, et al. (2011) ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma. J Pediatr Hematol Oncol 33: 360–368.
[17]
Stockwin LH, Vistica DT, Kenney S, Schrump DS, Butcher DO, et al. (2009) Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer 9: 22.
[18]
Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, et al. (2011) Molecular signatures database (MSigDB) 3.0. Bioinformatics 27: 1739–1740.
[19]
Kohonen T (1997) Self-Organizing Maps. Springer Series in Information Sciences, Second Edition. Berlin: Springer.
[20]
Koskimaki JE, Karagiannis ED, Rosca EV, Vesuna F, Winnard PT Jr, et al. (2009) Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia 11: 1285–1291.
[21]
Davicioni E, Wai DH, Anderson MJ (2008) Diagnostic and prognostic sarcoma signatures. Mol Diagn Ther 12: 359–374.
[22]
Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, et al. (2007) TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 67: 919–929.
[23]
Chiaverini C, Beuret L, Flori E, Busca R, Abbe P, et al. (2008) Microphthalmia-associated transcription factor regulates RAB27A gene expression and controls melanosome transport. J Biol Chem 283: 12635–12642.
[24]
Naran S, Zhang X, Hughes SJ (2009) Inhibition of HGF/MET as therapy for malignancy. Expert Opin Ther Targets 13: 569–581.
[25]
Ma CX, Janetka JW, Piwnica-Worms H (2011) Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 17: 88–96.
[26]
Zhang YW, Brognard J, Coughlin C, You Z, Dolled-Filhart M, et al. (2009) The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol Cell 35: 442–453.
[27]
Reed D, Altiok S (2011) Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine. Cancer Control 18: 188–195.
[28]
Cheung R, Malik M, Ravyn V, Tomkowicz B, Ptasznik A, et al. (2009) An arrestin-dependent multi-kinase signaling complex mediates MIP-1beta/CCL4 signaling and chemotaxis of primary human macrophages. J Leukoc Biol 86: 833–845.
[29]
Cambien B, Richard-Fiardo P, Karimdjee BF, Martini V, Ferrua B, et al. (2011) CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRbeta in colorectal carcinoma. PLoS One 6: e28842.
[30]
Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4: 540–550.
[31]
Cambien B, Karimdjee BF, Richard-Fiardo P, Bziouech H, Barthel R, et al. (2009) Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer 100: 1755–1764.
[32]
Erreni M, Bianchi P, Laghi L, Mirolo M, Fabbri M, et al. (2009) Expression of chemokines and chemokine receptors in human colon cancer. Methods Enzymol 460: 105–121.
[33]
Pradelli E, Karimdjee-Soilihi B, Michiels JF, Ricci JE, Millet MA, et al. (2009) Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int J Cancer 125: 2586–2594.
[34]
Kuriyama K, Todo S, Hibi S, Morimoto A, Imashuku S (2001) Alveolar soft part sarcoma with lung metastases. Response to interferon alpha-2a? Med Pediatr Oncol 37: 482–483.
[35]
Lindner DJ (2002) Interferons as antiangiogenic agents. Curr Oncol Rep 4: 510–514.
[36]
Coelho LF, Magno de Freitas Almeida G, Mennechet FJ, Blangy A, Uze G (2005) Interferon-alpha and -beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. Proc Natl Acad Sci U S A 102: 11917–11922.
[37]
Cronshaw DG, Owen C, Brown Z, Ward SG (2004) Activation of phosphoinositide 3-kinases by the CCR4 ligand macrophage-derived chemokine is a dispensable signal for T lymphocyte chemotaxis. J Immunol 172: 7761–7770.
[38]
Judson I (2010) Targeted therapies in soft tissue sarcomas. Ann Oncol 21Suppl 7: 277–280.
[39]
Judson I (2010) New treatments for sarcoma. Clin Adv Hematol Oncol 8: 244–246.
[40]
Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, et al. (2009) Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 15: 1096–1104.
[41]
Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, et al. (2012) Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: Results of a multicenter phase 2 trial. Cancer doi: 10.1002/cncr.27582.
[42]
Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S, et al. (2011) Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer 11: 541–557.
[43]
El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH, et al. (1990) Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1: 325–331.
[44]
Yee D, Favoni RE, Lebovic GS, Lombana F, Powell DR, et al. (1990) Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest 86: 1806–1814.
[45]
Anderson J, Gordon A, Pritchard-Jones K, Shipley J (1999) Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosomes Cancer 26: 275–285.
[46]
Prieur A, Tirode F, Cohen P, Delattre O (2004) EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 24: 7275–7283.
[47]
Zhan S, Shapiro DN, Helman LJ (1994) Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 94: 445–448.
[48]
Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, et al. (2012) An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol doi:10.1093/annonc/mds237.
